A clinical hold is implemented for IND which is a drug stage under clinical trials to investigate its efficacy & safety, and has not been officially allowed to market & used by patients.
The FDA has lifted the partial clinical hold it placed on a phase 1 trial of Mersana Therapeutics’ HER2-targeted antibody-drug conjugate (ADC). Regulatory officials put enrollment in the XMT-1522 breast cancer trial on hold in July after learning of the d